An interventional study of OptEx-TAVI and SoC-TAVI in Aortic Stenosis Disease and Valvular Heart Disease, sponsored by Ole De Backer. Recruiting at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Ole De Backer · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Aortic Valve Stenosis with a site in Belgium — 11 open to participants now, 14 under way, 1 of them phase 3. Aortic Valve Stenosis · Belgium.
Among the 47 studies in Aortic Valve Stenosis with a site in Belgium, this one is the 4th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 22 with no phase, reaches primary completion later than 11 of the 13 other live ones, and was the 47th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →11 of the 47 studies in Aortic Valve Stenosis with a site in Belgium are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Belgium, United States, Argentina and 20 more countries
Ages 6–11
Novartis Pharmaceuticals · Sites in Belgium, United States, Austria and 12 more countries
Ages 50–80
Université Libre de Bruxelles · Sites in Belgium
Ages 18+ · Healthy volunteers
National and Kapodistrian University of Athens · Sites in Belgium, Greece
Ages 18+
Niguarda Hospital · Sites in Belgium, Chile, Czechia and 2 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,010 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 214 across the 27 interventional studies, 569 across the 20 observational. Of the 27 that completed or were terminated, 9 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 47 have an industry lead sponsor. The 10 most frequent:
Ole De Backer is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Ole De Backer has 3 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Valve Stenosis with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies in Aortic Valve Stenosis with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Optimized Expansion of the implanted transcatheter aortic valve to reduce hypoattenuating leaflet thickening in non-atrial fibrillation patients undergoing transcatheter aortic valve implantation (TAVI): an international, multicentre, randomized controlled trial.
The objective is to evaluate whether TAVI with systematic optimized pre- and post-dilatation (optimized expansion (OptEx) TAVI strategy), compared to a standard of care (SoC) TAVI strategy, is superior in reducing hypoattenuating leaflet thickening as evaluated by cardiac computed tomography (CT) imaging at three months after TAVI.
The primary outcome is at least one thickened TAV leaflet involving ≥ 25% of the leaflet curvilinear dimension as assessed at cardiac CT at three months after TAVI.
A total of 1010 patients will be included in the OptEx-TAVI trial and randomised 1:1 to either :
All patients with indication for TAVI and eligible in relation to the study in- and exclusion criteria will be offered participation in the OptEx-TAVI trial.
Inclusion criteria:
Exclusion criteria:
Baseline characteristics, medical history, procedural details, electrocardiogram, echocardiography and cardiac CT-scan parameters will be recorded by assessing medical charts and patient interview.
During the TAVI-procedure, patients will be treated according to randomisation to either SoC or OptEx
Planned post-procedural visits at:
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
This study's planned enrollment of 1,010 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →Ole De Backer is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Compared within Aortic Valve Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Valve Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pre-dilatation and post-dialation optional, as per operator preference. The balloon size used for pre- or post-dilatation is left at the operator's discretion. Operators are only encouraged to post-dilate the implanted transcatheter aortic valve (TAV) in case of ≥ moderate paravalvular regurgitation or a suboptimal transvalvular gradient.
Procedure: SoC-TAVI
Systematic pre-dilatation and post-dilatation with an optimally-sized balloon
Procedure: OptEx-TAVI
During TAVI with either self-expanding or balloon-expandable TAVs: * Pre-dilatation: systematic pre-dilatation with an optimally-sized balloon. * Post-dilatation: systematic TAV post-dilatation with an optimally-sized balloon. Optimally-sized balloon: 1. The recommended balloon size used for pre- and post-dilatation is the perimeter-derived mean diameter of the native aortic annulus minus 1 mm and should never exceed the perimeter-derived mean diameter of the native aortic annulus. A smaller-sized balloon should be considered in case of severe left ventricular outflow tract calcium and/or severely calcified leaflets in combination with a shallow sinus of Valsalva. 2. In case of post-dilatation of the Evolut TAV (Medtronic, USA), the instructions for use (IFU) for post-dilatation of the Evolut valve should be respected. 3. Also, a balloon-expandable TAV has to be post-dilated with an optimally-sized balloon in case of randomization to the OptEx-TAVI arm.
During TAVI with either self-expanding or balloon-expandable TAVs: Pre-dilatation: optional, as per operator preference and post-dilatation: optional, as per operator preference. Operators are only encouraged to post-dilate the implanted TAV in case of ≥ moderate paravalvular regurgitation or a suboptimal transvalvular gradient. The balloon size used for pre- or post-dilatation is left at the operator's discretion.
At least one TAV leaflet with HALT
At least one TAV leaflet with hypoattenuated leaflet thickening (HALT) involving more than the base (≥ 25% of the leaflet curvilinear dimension) as assessed at cardiac CT-scan .
Time frame: At three months after TAVI
HALT 50%
At least one TAV leaflet with HALT involving ≥ 50% of the leaflet curvilinear dimension assessed by cardiac CT-scan
Time frame: At 3 months/At 1 year
HALT 25%
The rate of TAV leaflets with HALT involving ≥ 25% of the leaflet curvilinear dimension assessed by cardiac CT-scan
Time frame: At 3 months/At 1 year
HALT 50%, multiple
The rate of TAV leaflets with HALT involving ≥ 50% of the leaflet curvilinear dimension assessed by cardiac CT-scan
Time frame: At 3 months/At 1 year
Bioprosthetic leaflet micro-calcification target-to-background ratio
Ratio of bioprosthetic micro-calcification activity assessed by PET CT- scan by 18F-NaF uptake originating from the valve leaflets observed on 3 orthogonal planes after co-registration of background PET activity with contrast CT angiography. Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan
Time frame: At 5 years
Valve performance
Intended performance of the valve (mean gradient \< 20 mmHg, peak velocity \< 3 m/s, Doppler velocity index ≥ 0.25, and less than moderate aortic regurgitation) by TTE as per VARC- 3 criteria
Time frame: At 3 months/At 1 year
structural valve deterioration
Moderate or greater hemodynamic structural valve deterioration by TTE as per VARC-3 criteria. Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan
Time frame: At 5 years
Bioprosthetic valve dysfunction (BVD)
Severe bioprosthetic valve dysfunction (BVD) by TTE as per VARC-3 criteria. Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan
Time frame: At 5 years
Bioprosthetic valve failure (BVF)
As per VARC-3 criteria; Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan
Time frame: At 5 years
Technical success
As per VARC-3 criteria
Time frame: Periprocedural
Device success
as per VARC-3 criteria
Time frame: At 3 months
Early safety
As per VARC-3 criteria
Time frame: At 3 months
Clinical efficacy
As per VARC-3 criteria
Time frame: At 1 year
Valve-related long-term clinical efficacy
As per VARC-3 criteria; Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan
Time frame: At 5 years
Freedom from mortality
Freedom from mortality
Time frame: Periprocedural, at 3 months and at 1 year
Risk of cardiovascular mortality
Risk of cardiovascular mortality. VARC-3 criteria
Time frame: At 1 year
Risk of non-cardiovascular mortality
Risk of non-cardiovascular mortality. VARC-3 criteria
Time frame: At 1 year
Risk of acute kidney injury
Risk of acute kidney injury stage 3 or 4. VARC-3 criteria
Time frame: At 3 months
Risk of bleeding
Risk of VARC-3 type 2-4 bleeding
Time frame: At 3 months, 1 year and 5 years (Only for those patients alive at 5 years and volunteering to undergo a F-NaF PET-CT-scan)
Risk of stroke
Risk of all stroke
Time frame: At 3 months and 1 year
Risk of thomboembolism
Freedom from stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies). VARC-3 criteria.
Time frame: At 5 years
Rate of successful access
Successful access, delivery of the device, and retrieval of the delivery system
Time frame: Periprocedural
Freedom from surgery or intervention
Rate of freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication
Time frame: Periprocedural and at 3 months
Risk of vascular complications
Risk of major vascular, access-related, or cardiac structural complication, VARC-3 criteria.
Time frame: At 3 months
Risk of aortic prosthetic regurgitation
Freedom from moderate or severe aortic regurgitation. VARC-3 criteria
Time frame: At 3 months
Risk of permanent pacemaker
Risk of new permanent pacemaker due to procedure-related conduction abnormalities
Time frame: At 3 months
Risk of procedure or valve-related hospitalization
Risk of hospitalization for procedure- or valve-related causes. VARC-3
Time frame: At 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jul 2029, 44 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 44 months is close to that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.